Tiger Brokers

  • Quotes
  • Products
    • Cash Boost Account
    • US Stocks
    • US Fractional Shares
    • HK Stocks
    • China A-shares
    • Options
    • Futures
    • US Treasury
    • Auto-invest
    • Fixed Coupon Notes
    • Tiger BOSS Debit Card
    • Fund Mall
    • Tiger Vault
    • Tiger Open Platform
    • Wealth
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Tiger Vault
      • Features of Tiger Vault
      • Transaction Fees
    • Statement
      • Statement
      • Dividends
  • Learn
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
  • Careers
    • L.E.A.P Programme
    • Investment Representative
    • Careers Portal
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRAWS PHARMA

1.46
-0.0200-1.35%
Post-market: 1.45-0.0100-0.68%17:32 EDT
Volume:47.66K
Turnover:69.85K
Market Cap:8.12M
PE:-0.04
High:1.49
Open:1.46
Low:1.44
Close:1.48
Loading ...
OverviewCompanyNewsFilings

Traws Pharma Inc - No Significant Adverse Events Reported in Phase I Study

THOMSON REUTERS
·
23 Jan

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

PR Newswire
·
23 Jan

Traws Pharma files to sell 7.23M shares of common stock for holders

TIPRANKS
·
15 Jan

Traws Pharma, Expert Systems: Breakthrough in H5N1Bird Flu antiviral program

TIPRANKS
·
11 Jan

Expert Systems: Announced a Significant Milestone in a Development of Traws Pharma's H5n1 Antiviral Program

THOMSON REUTERS
·
11 Jan

Expert Systems: With Completion of Phase 1 Trials, Plans Are Underway to Initiate Phase 2 Efficacy Studies in First Half of 2025

THOMSON REUTERS
·
11 Jan

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

PR Newswire
·
11 Jan

Analyst Rate

 
 
 
 

Corporate Actions

Financial Report Announcement
May 15, 2025 Pre-Market
Financial Report Announcement
Mar 31, 2025 Pre-Market
Financial Report Announcement
Nov 14, 2024 Post Market
Split&Reverse Split
Sep 23, 2024 25 for 1
Financial Report Announcement
Aug 15, 2024 Pre-Market

Dividend History

no data

No relevant data is available

Valuation Analysis

-0.06
Current
-0.25
Sector Average
86.90%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-0.06
Maximum
-0.03
+1 STD
0.03
Minimum
-0.93
-1 STD
-0.52
Average
-0.25

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.